Related references
Note: Only part of the references are listed.Association of TIMP3 expression with vessel density, macrophage infiltration and prognosis in human malignant melanoma
Asha M. Das et al.
EUROPEAN JOURNAL OF CANCER (2016)
The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer
Su Wei et al.
BIOMEDICAL REPORTS (2016)
Tissue inhibitor of metalloproteinase-3 (TIMP3) promotes endothelial apoptosis via a caspase-independent mechanism
Jian Hua Qi et al.
APOPTOSIS (2015)
Prognostic significance of TIMP-2, MMP-2, and MMP-9 on high-grade serous ovarian carcinoma using digital image analysis
Patrice Desmeules et al.
HUMAN PATHOLOGY (2015)
Development and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovary
Hannah S. van Meurs et al.
GYNECOLOGIC ONCOLOGY (2014)
The Role of HE4 in Ovarian Cancer Follow-up A Review
Elisa Piovano et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)
TIMP-3 Expression Associates with Malignant Behaviors and Predicts Favorable Survival in HCC
Xuefeng Gu et al.
PLOS ONE (2014)
Meta-Analysis of MMP2, MMP3, and MMP9 Promoter Polymorphisms and Head and Neck Cancer Risk
Caiyun Zhang et al.
PLOS ONE (2013)
Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion
Xiaoxia Hu et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2012)
Human epididymis protein 4 (HE4) and ovarian cancer prognosis
Dominique Trudel et al.
GYNECOLOGIC ONCOLOGY (2012)
The Behavior of Matrix Metalloproteinases and Their Inhibitors in Colorectal Cancer
Laszlo Herszenyi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Expression of MMP-2,-7,-9, MT1-MMP and TIMP-1 and-2 has no prognostic relevance in patients with advanced epithelial ovarian cancer
Jean-Luc Brun et al.
ONCOLOGY REPORTS (2012)
Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer
Woo Dae Kang et al.
GYNECOLOGIC ONCOLOGY (2010)
The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Hannelore Denys et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma
L Manenti et al.
EUROPEAN JOURNAL OF CANCER (2003)
A prognostic model for ovarian cancer
TG Clark et al.
BRITISH JOURNAL OF CANCER (2001)
Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation
RR Baruch et al.
CELL BIOLOGY INTERNATIONAL (2001)
Share Paper
